Lucira Health Patents

Patent portfolio assigned to Lucira Health (verified via public assignee records). At-home molecular (LAMP) COVID-19 / COVID+flu test maker (formerly Diassess Inc). Filed bankruptcy Feb 2023; assets bought by Pfizer Apr 2023. Google Patents shows multiple patents assigned to Lucira Health Inc / Diassess Inc (e.g. US10253357B2 'Colorimetric detection of nucleic acid amplification', CA3073868A1), some later assigned to Pfizer -> has_patents true. Exact count not reliably visible; left 0. Cue Health and Detect are the direct DTC at-home molecular-test competitors.